Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...

ANX007 is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key ...

The “classical” pathway of the complement system is triggered when C1q binds to antibodies that are already bound to antigens on a cell surface. It only comes into effect when a high number of ...

Anti-C1q antibodies were positive. Other tests, including the extractable nuclear antigens (ENA), anti-dsDNA, antineutrophil cytoplasmic antibodies (ANCA), rheumatoid factor, HLA-B27, hepatitis B and ...

Immunological tests can differentiate proliferative from non-proliferative lupus nephritis, but anti-C1q antibodies and urinary erythrocytes have the best predictive power to dist ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from ...

ANX007 is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. ANX007 is the only investigational therapy in GA ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...